A premier syndicate of life sciences investors including Perceptive Advisors, Bain Capital Life Sciences (“Bain Capital”), and RA Capital Management (“RA Capital”) (collectively the “Investor Group”) together with Sarepta Therapeutics, Inc. (“Sarepta”) (NASDAQ: SRPT), a leader in precision genetic medicine for rare diseases, today announced a $107 million Series A financing to create AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases. The private financing round includes a $15 million equity investment from Sarepta.
Alexander “Bo” Cumbo, a seasoned biopharmaceutical executive, has been appointed AavantiBio’s Chief Executive Officer and President, effective immediately. Mr. Cumbo joins the Company after eight years at Sarepta, where he served as Chief Commercial Officer and Executive Vice President. He will continue to serve as an advisor to Sarepta through December 31, 2020.
Singapore has always had a progressive healthcare system with prioritizing innovative solutions to the existing…
A Ponzi scheme is a fraudulent investment scheme that aims to give its investors high…
According to the Global Prop tech Survey, 2019 published by KPMG one of the key…
In April 2016, the world witnessed one of the biggest information leaks in history, consisting…
Silent Eight a global technology company that helps combat money laundering and terrorism financing using…
Indian startup Gully Network Retail Pvt Ltd, a retail-tech startup focused on providing services to…
Leave a Comment